Effects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes

British Journal of Pharmacology

Volumn 171, Issue 14, 2014, Pages 3485-3498

  Al Kury, Lina T ^a   Voitychuk, Oleg I ^b   Yang, Keun Hang Susan ^c   Thayyullathil, Faisal T ^a   Doroshenko, Petro ^a   Ramez, Ali M ^a   Shuba, Yaroslav M ^b   Galadari, Sehamuddin ^a   Howarth, Frank Christopher ^a   Oz, Murat ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b BOGOMOLETZ INSTITUTE OF PHYSIOLOGY   (Ukraine)

^c CHAPMAN UNIVERSITY   (United States)

Author keywords

endocannabinoid; ventricular myocyte

Indexed keywords

ANANDAMIDE; BATRACHOTOXIN; CALCIUM CHANNEL L TYPE; ISRADIPINE; METHANANDAMIDE; PERTUSSIS TOXIN; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL; AMIDE; ARACHIDONIC ACID DERIVATIVE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID; ENDOCANNABINOID; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT;

ANIMAL CELL; ARTICLE; CALCIUM CURRENT; CONTROLLED STUDY; HEART MUSCLE CELL; HEART MUSCLE FIBER MEMBRANE; IC 50; NONHUMAN; PATCH CLAMP TECHNIQUE; PRIORITY JOURNAL; RAT; SODIUM CURRENT; ANIMAL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; HEART VENTRICLE; METABOLISM; STRUCTURE ACTIVITY RELATION; WISTAR RAT;

ANIMALS; ARACHIDONIC ACIDS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; HEART VENTRICLES; MYOCYTES, CARDIAC; POLYUNSATURATED ALKAMIDES; RATS; RATS, WISTAR; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84903177442     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12734     Document Type: Article

References (64)

1. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, et al. (1994). (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 37: 1889-1893.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The concise guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et al. (2013b). The concise guide to PHARMACOLOGY 2013/14: ion channels. Br J Pharmacol 170: 1607-1651
4. Al Kury LT, Voitychuk OI, Ali RM, Galadari S, Yang KH, Howarth FC, et al. (2014). Effects of endogenous cannabinoid anandamide on excitation-contraction coupling in rat ventricular myocytes. Cell Calcium 55: 104-118.
5. Alptekin A, Galadari S, Shuba Y, Petroianu G, Oz M, (2010). The effects of anandamide transport inhibitor AM404 on voltage-dependent calcium channels. Eur J Pharmacol 634: 10-15.
6. Amoros I, Barana A, Caballero R, Gomez R, Osuna L, Lillo MP, et al. (2010). Endocannabinoids and cannabinoid analogues block human cardiac Kv4.3 channels in a receptor-independent manner. J Mol Cell Cardiol 48: 201-210.
7. Andrag E, Curtis MJ, (2013). Feasibility of targeting ischaemia-related ventricular arrhythmias by mimicry of endogenous protection by endocannabinoids. Br J Pharmacol 169: 1840-1848.
8. Barana A, Amoros I, Caballero R, Gomez R, Osuna L, Lillo MP, (2010). Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner. Cardiovasc Res 85: 56-67.
9. Batkai S, Pacher P, (2009). Endocannabinoids and cardiac contractile function: pathophysiological implications. Pharmacol Res 60: 99-106.
10. Bebarova M, Matejovic P, Pasek M, Ohlidalova D, Jansova D, Simurdova M, et al. (2010). Effect of ethanol on action potential and ionic membrane currents in rat ventricular myocytes. Acta Physiol (Oxf) 200: 301-314.
11. Bendahhou S, Cummins TR, Agnew WS, (1997). Mechanism of modulation of the voltage-gated skeletal and cardiac muscle sodium channels by fatty acids. Am J Physiol 272: C592-C600.
12. Berger C, Schmid PC, Schabitz WR, Wolf M, Schwab S, Schmid HH, (2004). Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J Neurochem 88: 1159-1167.
13. Bonz A, Laser M, Kullmer S, Kniesch S, Babin-Ebell J, Popp V, et al. (2003). Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 41: 657-664.
14. Bouchard JF, Lepicier P, Lamontagne D, (2003). Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci 72: 1859-1870.
15. Catterall WA, Goldin AL, Waxman SG, (2005a). International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 57: 397-409.
16. Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J, (2005b). International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 57: 411-425.
17. Chemin J, Nargeot J, Lory P, (2007). Chemical determinants involved in anandamide-induced inhibition of T-type calcium channels. J Biol Chem 282: 2314-2323.
18. Danziger RS, Sakai M, Capogrossi MC, Spurgeon HA, Hansford RG, Lakatta EG, (1991). Ethanol acutely and reversibly suppresses excitation-contraction coupling in cardiac myocytes. Circ Res 68: 1660-1668.
19. Di Marzo V, De Petrocellis L, Bisogno T, (2005). The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb Exp Pharmacol 168: 147-185.
20. Duan Y, Zheng J, Nicholson RA, (2008). Inhibition of [3H]batrachotoxinin A-20α-benzoate binding to sodium channels and sodium channel function by endocannabinoids. Neurochem Int 52: 438-446.
21. Dunn SM, (1989). Voltage-dependent calcium channels in skeletal muscle transverse tubules. Measurements of calcium efflux in membrane vesicles. J Biol Chem 264: 11053-11060.
22. Epps DE, Schmid PC, Natarajan V, Schmid HH, (1979). N-acylethanolamine accumulation in infarcted myocardium. Biochem Biophys Res Commun 90: 628-633.
23. Epps DE, Mandel F, Schwartz A, (1982). The alteration of rabbit skeletal sarcoplasmic reticulum function by N-acylethanolamine, a lipid associated with myocardial infarction. Cell Calcium 3: 531-543.
24. Farkas A, Curtis MJ, (2003). Does QT widening in the Langendorff-perfused rat heart represent the effect of repolarization delay or conduction slowing? J Cardiovasc Pharmacol 42: 612-621.
25. Ford WR, Honan SA, White R, Hiley CR, (2002). Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol 135: 1191-1198.
26. Gulaya NM, Melnik AA, Balkov DI, Volkov GL, Vysotskiy MV, Vaskovsky VE, (1993). The effect of long-chain N-acylethanolamines on some membrane-associated functions of neuroblastoma C1300 N18 cells. Biochim Biophys Acta 1152: 280-288.
27. Hansen HS, Moesgaard B, Hansen HH, Petersen G, (2000). N-acylethanolamines and precursor phospholipids-relation to cell injury. Chem Phys Lipids 108: 135-150.
28. Hanus LO, Mechoulam R, (2010). Novel natural and synthetic ligands of the endocannabinoid system. Curr Med Chem 17: 1341-1359.
29. Howarth FC, Qureshi MA, White E, (2002). Effects of hyperosmotic shrinking on ventricular myocyte shortening and intracellular Ca(2+) in streptozotocin-induced diabetic rats. Pflugers Arch 444: 446-451.
30. Ishii I, Chun J, (2002). Anandamide-induced neuroblastoma cell rounding via the CB1 cannabinoid receptors. Neuroreport 13: 593-596.
31. Johnson DE, Heald SL, Dally RD, Janis RA, (1993). Isolation, identification and synthesis of an endogenous arachidonic amide that inhibits calcium channel antagonist 1,4-dihydropyridine binding. Prostaglandins Leukot Essent Fatty Acids 48: 429-437.
32. Kang JX, Leaf A, (1996). Evidence that free polyunsaturated fatty acids modify Na+ channels by directly binding to the channel proteins. Proc Natl Acad Sci U S A 93: 3542-3546.
33. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
34. Kim HI, Kim TH, Shin YK, Lee CS, Park M, Song JH, (2005). Anandamide suppression of Na+ currents in rat dorsal root ganglion neurons. Brain Res 1062: 39-47.
35. Krylatov AV, Uzhachenko RV, Maslov LN, Bernatskaya NA, Makriyannis A, Mechoulam R, (2002). Endogenous cannabinoids improve myocardial resistance to arrhythmogenic effects of coronary occlusion and reperfusion: a possible mechanism. Bull Exp Biol Med 133: 122-124.
36. Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, et al. (1999). Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 42: 769-776.
37. Li Q, Ma HJ, Zhang H, Qi Z, Guan Y, Zhang Y, (2009). Electrophysiological effects of anandamide on rat myocardium. Br J Pharmacol 158: 2022-2029.
38. Lozovaya N, Min R, Tsintsadze V, Burnashev N, (2009). Dual modulation of CNS voltage-gated calcium channels by cannabinoids: focus on CB1 receptor-independent effects. Cell Calcium 46: 154-162.
39. Malinowska B, Baranowska-Kuczko M, Schlicker E, (2012). Triphasic blood pressure responses to cannabinoids: do we understand the mechanism? Br J Pharmacol 165: 2073-2088.
40. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
41. McIntosh BT, Hudson B, Yegorova S, Jollimore CA, Kelly ME, (2007). Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells. Br J Pharmacol 152: 1111-1120.
42. Mendizabal VE, Adler-Graschinsky E, (2007). Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol 151: 427-440.
43. Montecucco F, Di Marzo V, (2012). At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol Sci 33: 331-340.
44. Nicholson RA, Liao C, Zheng J, David LS, Coyne L, Errington AC, (2003). Sodium channel inhibition by anandamide and synthetic cannabimimetics in brain. Brain Res 978: 194-204.
45. Oz M, (2006). Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. Pharmacol Ther 111: 114-144.
46. Oz M, Tchugunova YB, Dunn SM, (2000). Endogenous cannabinoid anandamide directly inhibits voltage-dependent Ca(2+) fluxes in rabbit T-tubule membranes. Eur J Pharmacol 404: 13-20.
47. Oz M, Tchugunova Y, Dinc M, (2004). Differential effects of endogenous and synthetic cannabinoids on voltage-dependent calcium fluxes in rabbit T-tubule membranes: comparison with fatty acids. Eur J Pharmacol 502: 47-58.
48. Oz M, Alptekin A, Tchugunova Y, Dinc M, (2005). Effects of saturated long-chain N-acylethanolamines on voltage-dependent Ca2+ fluxes in rabbit T-tubule membranes. Arch Biochem Biophys 434: 344-351.
49. Pacher P, Batkai S, Kunos G, (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462.
50. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB. Pharmacol Rev 62: 588-631.
51. Postma SW, Catterall WA, (1984). Inhibition of binding of [3H]batrachotoxinin A 20-α-benzoate to sodium channels by local anesthetics. Mol Pharmacol 25: 219-227.
52. Randall MD, Kendall DA, O'Sullivan S, (2004). The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 142: 20-26.
53. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, et al. (1999). Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126: 665-672.
54. Schmid HH, Berdyshev EV, (2002). Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: metabolism and function. Prostaglandins Leukot Essent Fatty Acids 66: 363-376.
55. Sheldon RS, Cannon NJ, Duff HJ, (1986). Binding of [3H]batrachotoxinin A benzoate to specific sites on rat cardiac sodium channels. Mol Pharmacol 30: 617-623.
56. Sheldon RS, Duff HJ, Thakore E, Hill RJ, (1994). Class I antiarrhythmic drugs: allosteric inhibitors of [3H] batrachotoxinin binding to rat cardiac sodium channels. J Pharmacol Exp Ther 268: 187-194.
57. Soldatov NM, Oz M, O'Brien KA, Abernethy DR, Morad M, (1998). Molecular determinants of L-type Ca2+ channel inactivation. Segment exchange analysis of the carboxyl-terminal cytoplasmic motif encoded by exons 40-42 of the human α1C subunit gene. J Biol Chem 273: 957-963.
58. Straiker AJ, Borden CR, Sullivan JM, (2002). G-protein α subunit isoforms couple differentially to receptors that mediate presynaptic inhibition at rat hippocampal synapses. J Neurosci 22: 2460-2468.
59. Su Z, Preusser L, Diaz G, Green J, Liu X, Polakowski J, et al. (2011). Negative inotropic effect of a CB2 agonist A-955840 in isolated rabbit ventricular myocytes is independent of CB1 and CB2 receptors. Curr Drug Saf 6: 277-284.
60. Theile JW, Cummins TR, (2011). Inhibition of Navβ4 peptide-mediated resurgent sodium currents in Nav1.7 channels by carbamazepine, riluzole, and anandamide. Mol Pharmacol 80: 724-734.
61. Ugdyzhekova DS, Bernatskaya NA, Stefano JB, Graier VF, Tam SW, Mekhoulam R, (2001). Endogenous cannabinoid anandamide increases heart resistance to arrhythmogenic effects of epinephrine: role of CB(1) and CB(2) receptors. Bull Exp Biol Med 131: 251-253.
62. Voitychuk OI, Asmolkova VS, Gula NM, Sotkis GV, Galadari S, Howarth FC, et al. (2012). Modulation of excitability, membrane currents and survival of cardiac myocytes by N-acylethanolamines. Biochim Biophys Acta 1821: 1167-1176.
63. Wagner JA, Jarai Z, Batkai S, Kunos G, (2001). Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol 423: 203-210.
64. Zhang ZS, Cheng HJ, Onishi K, Ohte N, Wannenburg T, Cheng CP, (2005). Enhanced inhibition of L-type Ca2+ current by β3-adrenergic stimulation in failing rat heart. J Pharmacol Exp Ther 315: 1203-1211.